Xtent News (NASDAQ:XTNT)
| Latest Xtent News Headlines | | Date | Time | Source | | | 06/20/2008 | 8:00AM | PRNUS | XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
MENLO PARK, Calif., June 20 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) announced today that Christopher M. Smith and Arthur T. Taylor have been appointed to the company's board of directors.
"We expect to benefit greatly from the complementary skill sets that Chris and Art will add to our board of directors... More...>> |
| 06/17/2008 | 8:30AM | PRNUS | XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
MENLO PARK, Calif., June 17 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced that the CUSTOM I two-year data that was published in the current issue of EuroIntervention was recognized by the journal's editorial board as one of the six best papers submitted to the journal this past winter. Lutz Buellesfeld... More...>> |
| 06/12/2008 | 4:39PM | PRNUS | XTENT Announces European Regulatory Update
MENLO PARK, Calif., June 12 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced a progress update regarding its application to the designated European Notified Body for CE Mark approval of its Custom NX(R) DES System. XTENT's European Notified Body confirmed that recently presented six-month follow up... More...>> |
| 05/13/2008 | 11:40AM | PRNUS | XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
Company Will Host Webcast to Review Data Tuesday, May 13 at 1:00 p.m. EDT (7:00 p.m. CEST)
BARCELONA, Spain and MENLO PARK, Calif., May 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced positive six-month follow-up data from the CUSTOM III clinical trial, which assessed the safety and efficacy of... More...>> |
| 05/07/2008 | 8:30AM | PRNUS | XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th
MENLO PARK, Calif., May 7 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona. The company will hold a... More...>> |
| 04/28/2008 | 7:05PM | PRNUS | XTENT Announces First Quarter 2008 Financial Results
Six-month CUSTOM III long and multi-lesion clinical trial data to be presented as late-breaking data at EuroPCR on Tuesday, May 13
MENLO PARK, Calif., April 28 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today reported financial results for the first quarter ended March 31, 2008.
The company reported a net... More...>> |
| 03/12/2008 | 8:30AM | PRNUS | XTENT to Present at Cowen and Company's 28th Annual Health Care Conference
MENLO PARK, Calif., March 12 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced that Gregory D. Casciaro, President and Chief Executive Officer, will present at Cowen and Company's 28th Annual Health Care Conference on Tuesday, March 18, 2008 at 9:30 a.m. Eastern. This event will be held at the Boston... More...>> |
| 02/19/2008 | 4:05PM | PRNUS | XTENT Announces 2007 Financial Results
MENLO PARK, Calif., Feb. 19 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today reported financial results for the fourth quarter and year ended December 31, 2007.
The company reported a net loss and net loss attributable to common stockholders of $11.9 million, or $0.52 per share, for the fourth quarter of 2007... More...>> |
| 02/12/2008 | 4:05PM | PRNUS | XTENT Announces 2007 Financial Results Conference Call
MENLO PARK, Calif., Feb. 12 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) announced that it will report its financial results for 2007 after market close on Tuesday, February 19, 2008. The company will hold a conference call the same day at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by... More...>> |
| 12/27/2007 | 6:00AM | PRNUS | XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
- Company continues U.S. pivotal trial discussions with FDA -
MENLO PARK, Calif., Dec. 27 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT), the developer of customizable drug-eluting stent (DES) systems, today announced that it has submitted its application to the designated European Notified Body for CE Mark approval... More...>> |
| 11/15/2007 | 8:30AM | PRNUS | XTENT to Present at Three Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 15 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced that it will present at three upcoming investor conferences. The presentation details are as follows:
Piper Jaffray 19th Annual Health Care Conference
Tuesday, November 27 at 8:30 a.m. ET
The Pierre New York, New... More...>> |
| 10/22/2007 | 6:30AM | PRNUS | XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
No New MACE, Zero Late Stent Thrombosis
WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced positive long-term follow-up data from the CUSTOM I and CUSTOM II single-arm prospective studies evaluating the safety and efficacy of its Custom NX(R) drug-eluting stent system in patients... More...>> |
| 10/16/2007 | 8:00AM | PRNUS | XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
Company Also to Host Drug-Eluting Stent Symposium and Analyst Webcast
MENLO PARK, Calif., Oct. 16 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES... More...>> |
| 09/12/2007 | 4:05PM | PRNUS | XTENT to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007
MENLO PARK, Calif., Sept. 12 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced that Timothy D. Kahlenberg, Chief Financial Officer, will present at the 4th annual Merriman Curhan Ford & Co. Investor Summit on Monday, September 17, 2007 at 10:45 a.m. Pacific. This event will be held at the Mark Hopkins... More...>> |
| 08/13/2007 | 6:41PM | PRNUS | XTENT Appoints Michael L. Eagle to Board of Directors
MENLO PARK, Calif., Aug. 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) announced today that Michael L. Eagle, former Vice President, Manufacturing, at Eli Lilly and Company, has been appointed to the company's Board of Directors.
"We are very fortunate to have Mike Eagle join our Board of Directors as we ramp... More...>> |
| 08/07/2007 | 4:07PM | PRNUS | XTENT Announces Second Quarter 2007 Financial Results
Conference Call Today at 2 p.m. (PT)
MENLO PARK, Calif., Aug. 7 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today reported financial results for the quarter ended June 30, 2007.
The company reported a net loss of $9.5 million for the second quarter of 2007, compared to a net loss of $5.7 million for the same... More...>> |
| 07/25/2007 | 4:02PM | PRNUS | XTENT Announces Second Quarter 2007 Financial Results Call and Extension of Lock-Up Agreements
MENLO PARK, Calif., July 25 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) announced that it will report its financial results for the second quarter 2007 after market close on Tuesday, August 7, 2007. The company will hold a conference call the same day at 2 p.m. Pacific Time (5 p.m. Eastern Time). The call will... More...>> |
| 05/22/2007 | 12:44PM | PRNUS | XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
Trial Included One of the Most Challenging Patient Populations Studied of Any Drug-Eluting Stent (DES) Clinical Trial
BARCELONA and MENLO PARK, Calif., May 22 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) announces positive six-month follow-up data from the CUSTOM II clinical trial, which assessed the safety and... More...>> |
| 05/22/2007 | 6:00AM | PRNUS | XTENT Announces Webcast and Conference Call to Discuss CUSTOM II Trial Six-Month Data Presented At EuroPCR Meeting
MENLO PARK, Calif., May 22 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT), developer of customizable drug-eluting stent (DES) systems, will host an analyst webcast, slide presentation and telebriefing to review the CUSTOM II six-month data Tuesday, May 22 at 2:00p.m. EDT (8:00p.m. CEST).
The event will follow... More...>> |
| 05/09/2007 | 4:30PM | PRNUS | XTENT Announces Acceptance of Custom II Trial Data for Late Breaking Clinical Trial Session at EuroPCR
Company Also to Host Symposium on Customizable Drug Eluting Stents, Live Case, and Analyst Webcast
MENLO PARK, Calif., May 9 /PRNewswire-FirstCall/ -- XTENT, Inc. (NASDAQ:XTNT) today announced that 6-month follow-up data from the CUSTOM II trial will be presented at EuroPCR, taking place May 22 to 25 in Barcelona. The... More...>> |
|
|
|